When cooking at home, measuring the health value of a meal involves reading nutritional information printed on food packages or searching for food items online. When eating out, however, information is far more limited.…
BioLife Solutions has been riding high on the biotech wave. However, the question is whether BioLife risen too much.
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to share results from their most…
Celladon has announced that its board of directors unanimously approved a strategic plan to pursue either an acquisition or a partnership.
24/7 Wall St. has taken a look at a few of the major ASCO winners so far. Color and background information has also been added on each, as well as how shares have been…
If there ever was a perfect storm for large pharmaceutical and big-cap biotech companies to make acquisitions to enhance growth it is now.
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
Genetically modified organisms (GMO) are bad for people, the environment, and water supplies, at least. This is according to the protestors involved in the “March Against Monsanto.” Their protests cover 421 cities, 48 countries,…
There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend Monitor.
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair share of attention so far…
If Merrill Lynch's Bob Hopkins and team are correct, Baxter International is worth a lot more than its current share price would indicate.
When investors see stocks run up 50% or more on a news release, they probably just assume the company is being acquired.
After looking at the recent recovery, and after looking over the more recent news that has come out after earnings, 24/7 Wall St. wants to see if MannKind shares have finally reached their bottom.